SIMABS
Agoralaan, Abis Abis /
3590 Diepenbeek
BE
SIMABS
Foundation date
22/08/2019
Sector
#Biotechnology / R&D ServicesSubsector
- #Therapeutics - Biosimilars
- #Therapeutics - Nucleic acid drugs
- #Therapeutics - Proteins
- #R&D Services - Cell culture
- #R&D Services - CMO (Contract Manufacturing Organization)
- #R&D Services - Synthesis services
Therapeutic areas
SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies.
Upcoming events
All events-
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB -
1212 '22
Type 2 Immunity in Homeostasis and Disease (2nd edition)
Event by: VIB -
2911 '22
BioFIT 2022
Event by: Eurasanté
Latest news
More news-
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
13 hours ago
Read more
-
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
Thursday September 29th 2022
Read more
-
FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
Tuesday September 27th 2022
Read more